Sponsored Research Agreement Sample Contracts

Editas Medicine, Inc. – Sponsored Research Agreement (October 23rd, 2018)

This Sponsored Research Agreement (this “Agreement”), dated as of June 7, 2018 (the “Effective Date”), is made by and between the Broad Institute, Inc. (“Broad”), a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142, and Editas Medicine, Inc. (“Company”), a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, Massachusetts 02141.  Each of Broad and Company may be referred to herein as a “Party” or together as the “Parties.”

Arvinas Holding Company, Llc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SPONSORED RESEARCH AGREEMENT (September 14th, 2018)

THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”) dated as of March 7, 2018 (the “Effective Date”), is entered into between The Silverstein Foundation For Parkinson’s With GBA, a Delaware corporation (the “TSF”) and Arvinas, Inc., a Delaware corporation (“Company”), having a place of business located at 5 Science Park, New Haven, CT 06511.

Arvinas Holding Company, Llc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SPONSORED RESEARCH AGREEMENT (August 30th, 2018)

THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”) dated as of March 7, 2018 (the “Effective Date”), is entered into between The Silverstein Foundation For Parkinson’s With GBA, a Delaware corporation (the “TSF”) and Arvinas, Inc., a Delaware corporation (“Company”), having a place of business located at 5 Science Park, New Haven, CT 06511.

Arvinas Holding Company, Llc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. YALE UNIVERSITY CORPORATE SPONSORED RESEARCH AGREEMENT (August 30th, 2018)

This is a CORPORATE SPONSORED RESEARCH AGREEMENT effective July 1, 2016, by and between YALE UNIVERSITY, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”) and Arvinas, Inc., a Delaware corporation, having its principal offices at 5 Science Park, 395 Winchester Avenue, New Haven, CT 06511 (the “Sponsor”).

Y-mAbs Therapeutics, Inc. – Exhibit D SPONSORED RESEARCH AGREEMENT (August 24th, 2018)

This Sponsored Research Agreement (this “Agreement”), effective as of the date of the signature of the underlying license agreement, SK2017-1696, dated November 13, 2017, (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and Y-mAbs Therapeutics, Inc., a Delaware corporation with a principal office at 750 3rd Avenue. New York, N.Y. 10017 (“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”. This Exhibit D, including Appendix A and Appendix B attached hereto, replaces the Exhibit D (including Appendix B) of the License Agreement for MSK’s technology “CD33 Antibodies and constructs thereof” between Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, Inc., dated November 10, 2017 in its entirety, and such original Exhibit D is hereby cancelled and void.

Y-mAbs Therapeutics, Inc. – SPONSORED RESEARCH AGREEMENT (August 24th, 2018)

This Sponsored Research Agreement (this “Agreement”), effective as of the date of the last signature below (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and YmAbs, a Delaware corporation with a principal office at 750 Third Avenue, New York, NY 1017,(“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”.

Y-mAbs Therapeutics, Inc. – Exhibit D SPONSORED RESEARCH AGREEMENT (August 22nd, 2018)

This Sponsored Research Agreement (this “Agreement”), effective as of the date of the signature of the underlying license agreement, SK2017-1696, dated November 13, 2017, (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and Y-mAbs Therapeutics, Inc., a Delaware corporation with a principal office at 750 3rd Avenue. New York, N.Y. 10017 (“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”. This Exhibit D, including Appendix A and Appendix B attached hereto, replaces the Exhibit D (including Appendix B) of the License Agreement for MSK’s technology “CD33 Antibodies and constructs thereof” between Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, Inc., dated November 10, 2017 in its entirety, and such original Exhibit D is hereby cancelled and void.

Editas Medicine, Inc. – Sponsored Research Agreement (August 7th, 2018)

This Sponsored Research Agreement (this “Agreement”), dated as of June 7, 2018 (the “Effective Date”), is made by and between the Broad Institute, Inc. (“Broad”), a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142, and Editas Medicine, Inc. (“Company”), a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, Massachusetts 02141.  Each of Broad and Company may be referred to herein as a “Party” or together as the “Parties.”

Aevi Genomic Medicine, Inc. – Amendment #2 to Sponsored Research Agreement (August 2nd, 2018)

This Amendment #2 to Sponsored Research Agreement (this “Amendment #2”), executed on November 12, 2014 (“Agreement”), is made and entered into as of February 16, 2017 (“Amendment #2 Effective Date”), by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital of Philadelphia (“CHOP”).

Ophthotech Corp. – UNIVERSITY OF PENNSYLVANIA MASTER SPONSORED RESEARCH AGREEMENT (August 1st, 2018)

This Sponsored Research Agreement (“Agreement”) is dated as of June 6, 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6283, and Ophthotech Corporation, a Delaware corporation (“Sponsor”), having a place of business at One Penn Plaza, Suite 3520, New York, NY 10119. Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.

Qrons Inc. – Qrons And Dartmouth College Enter into One Year Sponsored Research Agreement (July 18th, 2018)

Sponsored Research Agreement will allow for continued research in developing innovative 3D printable, bio compatible advanced materials and stem cell delivery techniques for Qrons' traumatic brain injury treatment. Qrons will also have the option to negotiate exclusive licenses.

Qrons Inc. – SPONSORED RESEARCH AGREEMENT (July 18th, 2018)

This Sponsored Research Agreement ("Agreement") is made and is effective as of 07/12/2018 ("Effective Date") by and between Trustees of Dartmouth College, a non-profit, private educational and research institution under the laws of the State of New Hampshire ("Dartmouth") and Qrons Inc., a publicly traded, preclinical biotechnology company with a principal place of business at 777 Brickell Avenue, Suite 500, Miami, FL 33131 ("Sponsor").

Arvinas Holding Company, Llc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. YALE UNIVERSITY CORPORATE SPONSORED RESEARCH AGREEMENT (June 22nd, 2018)

This is a CORPORATE SPONSORED RESEARCH AGREEMENT effective July 1, 2016, by and between YALE UNIVERSITY, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”) and Arvinas, Inc., a Delaware corporation, having its principal offices at 5 Science Park, 395 Winchester Avenue, New Haven, CT 06511 (the “Sponsor”).

Arvinas Holding Company, Llc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SPONSORED RESEARCH AGREEMENT (June 22nd, 2018)

THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”) dated as of March 7, 2018 (the “Effective Date”), is entered into between The Silverstein Foundation For Parkinson’s With GBA, a Delaware corporation (the “TSF”) and Arvinas, Inc., a Delaware corporation (“Company”), having a place of business located at 5 Science Park, New Haven, CT 06511.

Sarepta Therapeutics, Inc. – SPONSORED RESEARCH AGREEMENT (May 3rd, 2018)

THIS SPONSORED RESEARCH AGREEMENT (this "Agreement"), effective the 12th day of October, 2007 (the "Effective Date"), is entered into by and between AVI  BIOPHARMA, INC., an Oregon Corporation, with principal offices located at One SW Columbia, Suite 1105, Portland, Oregon 97258 ("Company"), and CHARLEY'S FUND, INC., a 501(c)(3) tax-exempt public non-profit organization with a mailing address of P.O. Box 297, South Egremont, MA, 01258 (the "Sponsor").

Sarepta Therapeutics, Inc. – FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT (May 3rd, 2018)

This FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT (the “Amendment”) is entered into effective as of May 28, 2009 (“Amendment Date”), by and between AVI BioPharma, Inc., an Oregon corporation having offices at 4575 SW Research Way, Suite 200, Corvallis, OR 97333 (the “Company”), and Charley's Fund, Inc., a 501(c)(3) tax-exempt public non-profit organization with a mailing address of P.O. Box 297, South Egremont, MA 01258 (the “Sponsor”) (each a “Party” and together the “Parties”), and amends that certain SPONSORED RESEARCH AGREEMENT, effective as of October 12, 2007, by and between the Parties (the “Agreement”), as follows.

Y-mAbs Therapeutics, Inc. – Exhibit D SPONSORED RESEARCH AGREEMENT (April 3rd, 2018)

This Sponsored Research Agreement (this “Agreement”), effective as of the date of the signature of the underlying license agreement, SK2017-1696, dated November 13, 2017, (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and Y-mAbs Therapeutics, Inc., a Delaware corporation with a principal office at 750 3rd Avenue. New York, N.Y. 10017 (“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”. This Exhibit D, including Appendix A and Appendix B attached hereto, replaces the Exhibit D (including Appendix B) of the License Agreement for MSK’s technology “CD33 Antibodies and constructs thereof” between Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, Inc., dated November 10, 2017 in its entirety, and such original Exhibit D is hereby cancelled and void.

Y-mAbs Therapeutics, Inc. – SPONSORED RESEARCH AGREEMENT (April 3rd, 2018)

This Sponsored Research Agreement (this “Agreement”), effective as of the date of the last signature below (“Effective Date”), is between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and YmAbs, a Delaware corporation with a principal office at 750 Third Avenue, New York, NY 1017,(“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”.

Synthetic Biologics, Inc. – Amendment 005 Sponsored Research Agreement (SRA) UTA12-000950 (the “Agreement”) Dated December 19, 2012 Between The University of Texas at Austin (the “University”) And Synthetic Biologics, Inc. (the “Sponsor”) (February 22nd, 2018)

The purpose of this Amendment to extend the Termination Date under the Agreement until January 17, 2019 in order to allow the University to continue the research, at no additional cost to Sponsor.

Aeglea BioTherapeutics, Inc. – SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (November 7th, 2017)

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”).  Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

Juno Therapeutics, Inc. – AMENDMENT NO. 3 TO SPONSORED RESEARCH AGREEMENT (August 3rd, 2017)

This Amendment No. 3 to Sponsored Research Agreement (this “Amendment No. 3”) is entered into and made effective as of May 2, 2017 (the “Amendment No. 3 Effective Date”) by and between Juno Therapeutics, Inc., (“Sponsor”), a Delaware corporation, and Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (“Institute”), a Washington nonprofit corporation.

Juno Therapeutics, Inc. – AMENDMENT NO. 2 TO SPONSORED RESEARCH AGREEMENT (August 3rd, 2017)

This Amendment No. 2 to Sponsored Research Agreement (this “Amendment No. 2”) is entered into and made effective as of March 31, 2017 (the “Amendment No. 2 Effective Date”) by and between Juno Therapeutics, Inc., (“Sponsor”), a Delaware corporation, and Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (“Institute”), a Washington nonprofit corporation.

Ampio Pharmaceuticals, Inc. – Sponsored Research Agreement Addendum No. 7 (Termination) June 30, 2017 (July 7th, 2017)

This addendum is being entered into to modify the Sponsored Research Agreement (SRA) dated September 1, 2009 made by and between Trauma Research LLC (“TRLLC”) and Ampio Pharmaceuticals, Inc. (the “Company” or “Ampio”, formerly DMI Life Sciences, Inc.)

Clementia Pharmaceuticals Inc. – COMMERCIAL SPONSORED RESEARCH AGREEMENT (June 30th, 2017)

THIS AGREEMENT is entered into this 21sr day of June, 2016 (the “Effective Date”) by Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit public benefit corporation with an address at 10901 N. Torrey Pines Road, La Jolla, California 92037 (“Institute”) and Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St West, Suite 550, Montreal, Quebec, H3Z 2Y5, Canada (hereinafter refe1Ted to as “Sponsor”).

Clementia Pharmaceuticals Inc. – COMMERCIAL SPONSORED RESEARCH AGREEMENT (June 7th, 2017)

THIS AGREEMENT is entered into this 21sr day of June, 2016 (the “Effective Date”) by Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit public benefit corporation with an address at 10901 N. Torrey Pines Road, La Jolla, California 92037 (“Institute”) and Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St West, Suite 550, Montreal, Quebec, H3Z 2Y5, Canada (hereinafter refe1Ted to as “Sponsor”).

Aevi Genomic Medicine, Inc. – Amendment #2 to Sponsored Research Agreement (May 10th, 2017)

This Amendment #2 to Sponsored Research Agreement (this “Amendment #2”), executed on November 12, 2014 (“Agreement”), is made and entered into as of November 30, 2016 (“Amendment #2 Effective Date”) by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital of Philadelphia (“CHOP”).

Aeglea BioTherapeutics, Inc. – SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (November 9th, 2016)

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”).  Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

Bellicum Pharmaceuticals, Inc – BELLICUM PHARMACEUTICALS, INC. SPONSORED RESEARCH AGREEMENT NO. 2 (August 8th, 2016)

THIS SPONSORED RESEARCH AGREEMENT (the “Agreement”) is entered into and made and effective as of May 20, 2016 (“Effective Date”) by and between BELLICUM PHARMACEUTICALS, INC., with offices at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030, United States of America (“Sponsor”), and ACADEMISCH ZIEKENHUIS LEIDEN, also acting under the name Leiden University Medical Centre, with offices at Albinusdreef 2, 2333 ZA Leiden, The Netherlands (“Leiden”). Sponsor and Leiden are referred to herein collectively as the “Parties” or individually as a “Party.”

Mustang Bio, Inc. – SPONSORED RESEARCH AGREEMENT (July 28th, 2016)

THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”), dated as of March [ ], 2015 (the “Effective Date”), between Mustang Therapeutics, Inc., a Delaware corporation (“Company”) having an address of 3 Columbus Circle, New York, NY 10019, and City of Hope National Medical Center and Beckman Research institute of the City of Hope, each a California non-profit public benefit corporation (collectively, “COH”) having an address of 1500 East Duarte Road, Duarte, California 91010-3000.

Bio-Path Holdings Inc – Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer Sponsored Research Agreement will Evaluate DNAbilize™ Technology as a Cancer Vaccine to Activate Patients’ Immune Systems to Fight Cancer (July 1st, 2016)

HOUSTON—June 28, 2016 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid drugs, today announced that it has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer.

Aeglea BioTherapeutics, Inc. – SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (March 14th, 2016)

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

Atrinsic, Inc. – SPONSORED RESEARCH AGREEMENT (February 12th, 2016)

WHEREAS the parties have entered into a Technology License Agreement effective July 21, 2005, as amended, (collectively, the “License Agreement”)

Medgenics, Inc. – Amendment #1 to Sponsored Research Agreement (December 22nd, 2015)

This Amendment #1 to Sponsored Research Agreement, executed on November 12, 2014 (“Agreement”), is made and entered into as of December 18, 2015 (“Amendment #1 Effective Date”) by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital of Philadelphia (“CHOP”).

OncoCyte Corp – Third Amendment to the Sponsored Research Agreement (December 21st, 2015)

This THIRD AMENDMENT TO THE SPONSORED RESEARCH AGREEMENT (the "Third Amendment") is made as of the date of the last signature below (the "Third Amendment Effective Date"), by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a Pennsylvania nonprofit corporation located at 3601 Spruce Street, Philadelphia, PA 19104 ("Wistar"), and ONCOCYTE CORPORATION, a corporation organized under the laws of California, with a principal place of business located at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Sponsor"). Wistar and Sponsor shall be referred to herein individually as a "Party" and collectively as the "Parties."

OncoCyte Corp – Second Amendment to the Sponsored Research Agreement (November 23rd, 2015)

This SECOND AMENDMENT TO THE SPONSORED  RESEARCH AGREEMENT (the "Second Amendment") is made as of the date of the last signature below (the "Second Amendment Effective Date"), by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a Pennsylvania nonprofit corporation located at 3601 Spruce Street, Philadelphia, PA 19104 ("Wistar"), and ONCOCYTE CORPORATION, a corporation organized under the laws of California, with a principal place of business located at 1301 Harbor Bay Parkway, Alameda, CA 94502 ("Sponsor"). Wistar and Sponsor shall be referred to herein individually as a "Party" and collectively as the "Parties."